Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.68 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.54 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.54 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.54 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | JAK1 | P23458 | 2/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | LIPE | Q05469 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | PREP | P48147 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL371917 | 1.00 | NR1H2 (0.68) | NR1H2CHRM2CHRM1CHRM3USP2 | |
| SCHEMBL1425514 | 1.00 | NR1H2 (0.68) | NR1H2CHRM2CHRM1CHRM3USP2 | |
| SCHEMBL30988546 | 1.00 | NR1H2 (0.68) | NR1H2CHRM2CHRM1CHRM3USP2 | |
| SCHEMBL20936763 | 1.00 | NR1H2 (0.68) | NR1H2CHRM2CHRM1CHRM3USP2 | |
| SCHEMBL20566533 | 1.00 | NR1H2 (0.68) | NR1H2CHRM2CHRM1CHRM3USP2 | |
| SCHEMBL24740662 | 1.00 | NR1H2 (0.68) | NR1H2CHRM2CHRM1CHRM3USP2 | |
| SCHEMBL904134 | 1.00 | NR1H2 (0.68) | NR1H2CHRM2CHRM1CHRM3USP2 | |
| SCHEMBL903881 | 1.00 | NR1H2 (0.68) | NR1H2CHRM2CHRM1CHRM3USP2 | |
| SCHEMBL20936755 | 1.00 | NR1H2 (0.68) | NR1H2CHRM2CHRM1CHRM3USP2 | |
| SCHEMBL19456156 | 0.90 | NR1H2 (0.74) | NR1H2CHRM2CHRM1CHRM3USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105299-A1 | c-MET MODULATORS AND METHODS OF USE | EXELIXIS, INC (US) | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105299-A1 | c-MET MODULATORS AND METHODS OF USE | FLT4, MET, FLT1 | NR1H2 3959/4885CHRM2 2335/4885CHRM1 2570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.